Intra-Cellular Therapies (ITCI) Receives a Buy From RBC Capital
RBC Raises Price Target on Intra-Cellular Therapies to $107 From $103, Keeps Outperform Rating
UBS Downgrades Intra-Cellular Therapies to Neutral, Lowers Price Target to $83
Intra-Cellular Therapies Analyst Ratings
Mizuho Maintains Buy on Intra-Cellular Therapies, Raises Price Target to $100
Mizuho Securities Adjusts Intra-Cellular Therapies Price Target to $100 From $96, Maintains Buy Rating
Canaccord Genuity Maintains Buy on Intra-Cellular Therapies, Raises Price Target to $113
Intra-Cellular Therapies Analyst Ratings
Needham Maintains Buy on Intra-Cellular Therapies, Raises Price Target to $94
Intra-Cellular Therapies Analyst Ratings
Cantor Fitzgerald Reiterates Overweight on Intra-Cellular Therapies, Maintains $120 Price Target
Intra-Cellular Therapies Analyst Ratings
JP Morgan Maintains Overweight on Intra-Cellular Therapies, Raises Price Target to $78
Analysts' Opinions Are Mixed on These Healthcare Stocks: Veeva Systems (VEEV), Intra-Cellular Therapies (ITCI) and Phreesia (PHR)
Buy Rating Affirmed on Intra-Cellular Therapies Amid Strong Sales and Promising Clinical Trials
RBC Capital Remains a Buy on Intra-Cellular Therapies (ITCI)
Intra-Cellular Therapies Analyst Ratings
Needham Reiterates Buy on Intra-Cellular Therapies, Maintains $90 Price Target
Intra-Cellular Therapies: A Hold Rating Amid Anticipation of Critical Phase 3 Data and Diverse Clinical Pipeline
Needham: Reiterates Intra-Cellular Therapies (ITCI.US) buy rating with a target price of $90.00.